Alfred A. Renzi is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of hypolipidemic agents. With a total of 4 patents to his name, Renzi's work has had a meaningful impact on the treatment of hyperlipidemia.

Latest Patents

Renzi's latest patents include innovative compounds aimed at addressing cholesterol-related health issues. One of his notable inventions is a class of substituted or unsubstituted benzylaminobenzene alkanoic or alkenoic acids, which are disclosed as hypolipidemic agents, especially as hypocholesterolemic agents. This patent also includes methods of use and pharmaceutical compositions thereof. Another significant patent involves the compound 4-((3-methoxyphenyl)methyl)amino)benzoic acid, which is used to treat hyperlipidemia, particularly hypercholesterolemia, along with its pharmaceutically acceptable salts and compositions.

Career Highlights

Alfred A. Renzi is currently associated with The Dow Chemical Company, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments that help manage cholesterol levels in patients.

Collaborations

Renzi has collaborated with esteemed colleagues such as Eugene R. Wagner and Donald Paul Matthews, contributing to a rich environment of innovation and research.

Conclusion

Alfred A. Renzi's contributions to the field of hypolipidemic agents highlight his role as a significant inventor in the pharmaceutical industry. His patents reflect a commitment to improving health outcomes related to cholesterol management.